#Liechtenstein #Vaduz #Implantica #RefluxStop #Q3 2026

Implantica to Present Q3 2026 Results

Implantica AG, a leading medtech company, has announced an important event for investors. The company is set to present its results for the third quarter of 2026 (Q3 2026) on November 19, 2026, at 15:00 CET. This presentation is a key opportunity for stakeholders to gain insights into the company’s performance and future outlook.

Overview of the Presentation

Interested parties can tune in to the live event via a webcast. Those who wish to participate can access the presentation through the following link: Implantica Q3 2026 Presentation. Alternatively, a teleconference option will also be available for those interested in joining the discussion by phone. To participate via teleconference, registration is required, and participants will receive a dial-in number along with a conference ID after completing registration. For more information on the teleconference, visit: Implantica Q3 Teleconference.

The presentation will be given in English, allowing a wider audience to engage with the company’s updates. Key speakers scheduled for the event include CEO Peter Forsell, CFO Andreas Öhrnberg, and Chief Corporate Affairs Officer Nicole Pehrsson. Their insights will likely cover updates on product development as well as financial performance, providing valuable context for investors.

Key Highlights of Q3 2026

Ahead of the event, it is important to note that the interim report for Q3 2026 will be published earlier that same day at 8:00 AM CET. This report will provide preliminary insights into Implantica’s financial health and operational performance over the past quarter, reflecting any significant developments or challenges that may have influenced the company’s results.

Implantica, which is listed on the Nasdaq First North Premier Growth Market in Stockholm under the ticker IMP A SDB, is focused on innovative solutions in medical technology. The firm is well-known for its flagship product, RefluxStop®, an implant aimed at treating gastroesophageal reflux disease (GERD). This FDA-approved device offers a promising alternative to traditional anti-reflux surgeries typically associated with uncomfortable side effects. RefluxStop® aims to maintain the anatomical positioning of the lower esophageal sphincter, minimizing complications and enhancing patient recovery.

Looking Ahead

As Implantica continues to innovate within the realm of medical technology, the third quarter presentation is an exciting occasion for investors and industry stakeholders alike. The company has a robust pipeline of products, part of which integrates eHealth platforms for monitoring and controlling implants, along with wireless power solutions for medical devices.

These developments not only enhance the company's competitive positioning but also signify advancements that could potentially lower healthcare costs through preventative measures. The future looks promising for Implantica as it aims to further solidify its role as a leader in gastroenterology procedures and expand its influence in the medtech landscape.

Potential participants are encouraged to stay updated on the developments and outcomes of the presentation that could play a crucial role in shaping investor sentiment and expectations for Implantica as they move forward into the fourth quarter of 2026 and beyond.